These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 23566679)

  • 1. B-cell targeted therapeutics in clinical development.
    Blüml S; McKeever K; Ettinger R; Smolen J; Herbst R
    Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S4. PubMed ID: 23566679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
    Tanaka Y
    Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
    Reddy V; Jayne D; Close D; Isenberg D
    Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S2. PubMed ID: 23566295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell depletion in autoimmune disease.
    Gorman C; Leandro M; Isenberg D
    Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S17-21. PubMed ID: 15180893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell depletion and repopulation in autoimmune diseases.
    Pers JO; Daridon C; Bendaoud B; Devauchelle V; Berthou C; Saraux A; Youinou P
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):50-5. PubMed ID: 18270858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.
    Uzzan M; Colombel JF; Cerutti A; Treton X; Mehandru S
    Dig Dis Sci; 2016 Dec; 61(12):3407-3424. PubMed ID: 27655102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 8. Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.
    Levesque MC
    Clin Exp Immunol; 2009 Aug; 157(2):198-208. PubMed ID: 19604259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
    Mani LY; Vogt B; Burnier M; Golshayan D
    Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell-directed therapy for inflammatory skin diseases.
    Nagel A; Hertl M; Eming R
    J Invest Dermatol; 2009 Feb; 129(2):289-301. PubMed ID: 19148218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell targeted therapies in human autoimmune diseases: an updated perspective.
    Townsend MJ; Monroe JG; Chan AC
    Immunol Rev; 2010 Sep; 237(1):264-83. PubMed ID: 20727041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of systemic autoimmune and inflammatory diseases with rituximab].
    Bussone G; Hachulla E; Sibilia J; Michel M; Godeau B; Guillevin L; Mouthon L
    Presse Med; 2009 May; 38(5):808-23. PubMed ID: 19297127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [B-cell-targeted therapy in the treatment of autoimmune diseases].
    Roll P; Tony HP
    Z Rheumatol; 2009 May; 68(3):255-9. PubMed ID: 19384549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies for systemic lupus erythematosus: cellular targets.
    Looney RJ; Anolik J; Sanz I
    Rheum Dis Clin North Am; 2006 Feb; 32(1):201-15, xi. PubMed ID: 16504831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in B-cell targeting therapy for the treatment of systemic lupus erythematosus].
    Tanaka Y
    J UOEH; 2011 Jun; 33(2):173-81. PubMed ID: 21702122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD20 monoclonal antibodies: beyond B-cells.
    Avivi I; Stroopinsky D; Katz T
    Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus].
    Terrier B; Mouthon L
    Med Sci (Paris); 2013 Jan; 29(1):65-73. PubMed ID: 23351696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biotherapy of auto-immune diseases : past, present and future perspectives].
    Arnaud L; Haroche J; Piette JC; Amoura Z
    Presse Med; 2009 May; 38(5):749-60. PubMed ID: 19303737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.